Calton & Associates’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $647K | Buy |
26,875
+1,188
| +5% | +$31.1K | 0.09% | 191 |
|
|
2026
Q1 | $721K | Sell |
25,687
-5,843
| -19% | -$156K | 0.1% | 182 |
|
|
2025
Q4 | $785K | Buy |
31,530
+6,860
| +28% | +$173K | 0.12% | 175 |
|
|
2025
Q3 | $629K | Buy |
24,670
+7,012
| +40% | +$173K | 0.09% | 192 |
|
|
2025
Q2 | $428K | Sell |
17,658
-734
| -4% | -$17.1K | 0.07% | 229 |
|
|
2025
Q1 | $466K | Buy |
18,392
+5,909
| +47% | +$155K | 0.11% | 180 |
|
|
2024
Q4 | $331K | Sell |
12,483
-4,982
| -29% | -$135K | 0.15% | 142 |
|
|
2024
Q3 | $505K | Sell |
17,465
-7,712
| -31% | -$225K | 0.19% | 118 |
|
|
2024
Q2 | $704K | Buy |
25,177
+15,743
| +167% | +$433K | 0.35% | 71 |
|
|
2024
Q1 | $262K | Sell |
9,434
-2,173
| -19% | -$60.3K | 0.13% | 149 |
|
|
2023
Q4 | $334K | Buy |
+11,607
| New | +$351K | 0.13% | 151 |
|
|
2023
Q3 | – | Sell |
-14,073
| Closed | -$516K | – | 214 |
|
|
2023
Q2 | $516K | Buy |
14,073
+4,356
| +45% | +$170K | 0.24% | 102 |
|
|
2023
Q1 | $396K | Sell |
9,717
-2,016
| -17% | -$87.1K | 0.18% | 122 |
|
|
2022
Q4 | $601K | Buy |
11,733
+2,591
| +28% | +$124K | 0.23% | 109 |
|
|
2022
Q3 | $400K | Sell |
9,142
-3,193
| -26% | -$155K | 0.23% | 109 |
|
|
2022
Q2 | $646K | Sell |
12,335
-3,807
| -24% | -$194K | 0.36% | 72 |
|
|
2022
Q1 | $835K | Sell |
16,142
-875
| -5% | -$45.4K | 0.25% | 109 |
|
|
2021
Q4 | $1M | Sell |
17,017
-3,760
| -18% | -$186K | 0.27% | 101 |
|
|
2021
Q3 | $893K | Sell |
20,777
-5,854
| -22% | -$259K | 0.2% | 129 |
|
|
2021
Q2 | $1.04M | Sell |
26,631
-2,616
| -9% | -$102K | 0.2% | 108 |
|
|
2021
Q1 | $1.06M | Sell |
29,247
-1,958
| -6% | -$69.5K | 0.21% | 94 |
|
|
2020
Q4 | $1.15M | Buy |
31,205
+195
| +0.6% | +$7.15K | 0.21% | 92 |
|
|
2020
Q3 | $1.08M | Buy |
31,010
+8,153
| +36% | +$286K | 0.22% | 83 |
|
|
2020
Q2 | $709K | Sell |
22,857
-2,140
| -9% | -$72.7K | 0.15% | 110 |
|
|
2020
Q1 | $774K | Sell |
24,997
-291
| -1% | -$9.92K | 0.19% | 101 |
|
|
2019
Q4 | $940K | Buy |
25,288
+5,110
| +25% | +$182K | 0.19% | 97 |
|
|
2019
Q3 | $688K | Buy |
20,178
+1,768
| +10% | +$64.3K | 0.15% | 119 |
|
|
2019
Q2 | $757K | Sell |
18,410
-276
| -1% | -$11K | 0.21% | 83 |
|
|
2019
Q1 | $753K | Sell |
18,686
-710
| -4% | -$28.4K | 0.23% | 79 |
|
|
2018
Q4 | $803K | Buy |
19,396
+8,150
| +72% | +$338K | 0.3% | 68 |
|
|
2018
Q3 | $470K | Buy |
11,246
+214
| +2% | +$8.24K | 0.14% | 125 |
|
|
2018
Q2 | $433K | Sell |
11,032
-11,529
| -51% | -$394K | 0.13% | 136 |
|
|
2018
Q1 | $760K | Buy |
22,561
+2,058
| +10% | +$70.8K | 0.22% | 93 |
|
|
2017
Q4 | $716K | Buy |
+20,503
| New | +$699K | 0.18% | 103 |
|
Other funds holding PFE
Calton & Associates's PFE Position: Q2 2026 in Review
Calton & Associates increased its Pfizer (PFE) stake by 4.6% in Q2 2026, buying an estimated $31.1K and bringing the position to 26,875 shares worth $647K. The position accounts for 0.09% of the portfolio, ranked #191.
Calton & Associates first reported a position in PFE in Q4 2017 and has held it in 34 quarters since. The position peaked at $1.15M in Q4 2020. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Calton & Associates held 26,875 shares of Pfizer worth $647K as of Q2 2026.
- Calton & Associates bought 1,188 Pfizer shares in Q2 2026, an estimated $31.1K.
- Pfizer made up 0.09% of Calton & Associates's portfolio in Q2 2026, its #191 holding.
- Calton & Associates first reported a position in Pfizer in Q4 2017 and has held it in 34 quarters since.
- Calton & Associates's Pfizer position peaked at $1.15M in Q4 2020.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Calton & Associates's 13F filing for Q2 2026, filed 10 Aug 2026.